Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

@inproceedings{Alam2014SafetyTA,
  title={Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study},
  author={Mohammed Y. Alam and Paula L Jacobsen and Yinzhong Chen and Michael Serenko and Atul R. Mahableshwarkar},
  booktitle={International clinical psychopharmacology},
  year={2014}
}
Patients with major depressive disorder often experience relapse after responding to treatment; therefore, maintenance therapy with antidepressants is recommended for maintaining response or remission. This multicenter, open-label, flexible-dose, 52-week extension study evaluated the long-term safety, tolerability, and maintenance of efficacy in study participants who had completed one of two randomized, double-blind, placebo-controlled, 8-week dose-ranging vortioxetine trials in study… CONTINUE READING
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Practice guideline for the treatment of patients with major depressive disorder, 3rd ed

  • National Guideline Clearinghouse
  • Agency for Healthcare Research and Quality (AHRQ…
  • 2013
2 Excerpts

Similar Papers

Loading similar papers…